Psychedelics and Pro-Social Behaviors: A Perspective on Autism Spectrum Disorders
Xue Wang, Cong Lin, Xiaohui Wang
ACS Pharmacology & Translational Science February 10, 2025 DOI: 10.1021/acsptsci.5c00034 (opens in new tab) via OpenAlex
Summary
AI-generated from the abstractPsychedelics like LSD, psilocybin, and MDMA may enhance pro-social behaviors in people with autism spectrum disorders by altering brain circuits involved in social cognition. The viewpoint discusses potential mechanisms underlying these effects, such as increased neuroplasticity and changes in serotonin receptor activity. While direct evidence in ASD populations is limited, the authors suggest that these compounds could offer new therapeutic avenues for improving social interaction and communication deficits. The paper calls for further research to explore the safety and efficacy of psychedelic-assisted therapy for autism, emphasizing the need for controlled clinical trials.
Study at a glance
| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Interventions | LSD psilocybin MDMA |
| Keywords | Mental health treatment Psychedelics Autism spectrum disorders Neuroscience Social cognition |
| Citations | 5 |
| Key finding | Proposes that psychedelics may positively influence pro-social behaviors in individuals with ASD through modulation of neural pathways, but emphasizes the need for further research. |
Abstract
Autism Spectrum Disorders (ASD) are complex neurodevelopmental conditions characterized by deficits in social interaction, communication, and repetitive behaviors. This viewpoint explores the potential mechanisms through which psychedelics such as lysergic acid diethylamide (LSD), psilocybin, and 3,4-methylenedioxymethamphetamine (MDMA) may positively influence pro-social behaviors, focusing on their implications for individuals with ASD.